Decision IntelInsys Therapeutics
Insys Therapeutics Opioid Fraud
Estimated impact: $225M DOJ settlement; executives imprisoned; company bankrupt
Insys marketed sublingual fentanyl spray (Subsys) for non-cancer pain through a systematic bribery scheme. Sales reps were trained to deceive insurance prior-authorization processes, and the company paid kickbacks to prescribing physicians. The founder and executives were convicted of RICO charges.
Decision context
Whether to implement a sales strategy that involved bribing physicians and defrauding insurance companies to expand off-label use of a potent fentanyl product.
What the company’s own filing already carried
Not our reading of a memo. Insys Therapeutics's own 10-K, filed 2015-03-03 (10 months before the 2016 decision), was read by the audit engine's deterministic structural layer: the same detectors that run on every audit, with no language model involved. Everything below is drawn from the company's own disclosure, before any knowledge of what followed, and never from the decision itself.
Survivable as structured: if the flagged risk fires, the deal has the exits, cushions, or staging to absorb the hit and continue.
The structural layer flagged no unabsorbed condition in this filing.
- This reads the company's own 10-K (filed 10 months before the decision), not the decision memo itself, so it can only understate what a full audit of the memo would surface.
- It reads the structure of the situation, not the trigger: whether a shock to the flagged conditions would be absorbed, never that a shock arrives.
- A reading of a dated filing, not a prediction: every condition can be checked against the company's own 10-K.
Decision anatomy
Red = risk factor present · Green = protective factor present
Biases present in the decision
★ Primary driver · Severity estimated from bias type and decision outcome
Toxic combinations
The curated library this case sits in
Across all 155 curated case studies in our library, by documented outcome:
The library is curated toward documented failures, so this split describes the library, not the base rate of deals. The case above is one row in it.
Lessons learned
- Groupthink in a sales-driven culture normalized fraud when leadership framed kickbacks as standard industry practice
- Authority bias from the founder (John Kapoor) made employees reluctant to question obviously illegal directives
- Framing the prior-authorization gaming as "patient access" masked the ethical and legal reality
Source: DOJ Press Release, "Founder and Four Executives of Insys Therapeutics Convicted of RICO Conspiracy" (2019) (Case Study)
These patterns were flaggable in Insys Therapeutics's own record — before the outcome.
See the full reasoning audit we ran — no login, no card. Then run the same audit on a deal you have already closed.
Or leave your email, we'll run the audit on a deal of your choosing and send the readout within a business day.
Workflows that fire on decisions like Insys Therapeutics’s
The same Recognition-Rigor Framework that documents this case audits memos in the same shape — before the outcome forces the lesson.